Fig. 1From: Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancera Progression free survival (PFS) and b Overall Survival (OS) in HER2-positive (n = 29) and HER2-negative (n = 40) gastric cancer patients. p-values were calculated using the log rank (Mantel–Cox) test with GraphPad PrismBack to article page